A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation for Refractory or Relapsed Hematologic Malignancies, With Cyclosporine and Methotrexate for Graft-Versus-Host Disease Prophylaxis.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ciclosporin; Ciclosporin; Cyclophosphamide; Doxorubicin; Etoposide; Fludarabine; Methotrexate; Prednisone; Rituximab; Vincristine
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Graft-versus-host disease; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 09 Sep 2021 Biomarkers information updated
- 24 Aug 2011 Planned end date (Oct 2005) added as reported by ClinicalTrials.gov.
- 24 Aug 2011 Planned end date (Oct 2005) added as reported by ClinicalTrials.gov.